Adicet bio reports fourth quarter and full year 2024 financial results and highlights recent company progress

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended december 31, 2024. “in 2025 we plan to continue advancing our gamma delta 1 car t cell therapy programs, achieving key milestones and reporting preliminary data in autoimmune and.
ACET Ratings Summary
ACET Quant Ranking